DeCure for Beta-thalassemia-X-linked thrombocytopenia syndrome
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for beta-thalassemia-X-linked thrombocytopenia syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBeta-thalassemia-X-linked thrombocytopenia syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for beta-thalassemia-x-linked thrombocytopenia syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 2010 review of Wiskott-Aldrich syndrome states that mutations in the WAS gene cause classic WAS, X-linked thrombocytopenia, and X-linked neutropenia, each with distinct clinical severity. The review notes improved outcomes for stem cell transplantation from matched donors and early promising results from the first clinical gene therapy trial, but provides no survival or response rate numbers. No drug treatment is mentioned.
A 2002 case report describes pulmonary thromboembolism in a 61-year-old woman with beta-thalassemia intermedia and no other thrombosis risk factors, documented by perfusion lung scan. The report notes a significant relationship between pulmonary thromboembolism and pulmonary hypertension in these patients. A separate review of hypercoagulability in beta-thalassemia identifies a high incidence of thromboembolic events, mainly in beta-thalassemia intermedia, and discusses recommendations for thrombosis prophylaxis, but gives no specific drug or trial data.
A 2007 randomised single-blinded trial of 60 beta-thalassemia patients tested Yisui Shengxue Granule (YSSXG), a compound traditional Chinese herbal medicine, against placebo for three months. In the YSSXG group (n=30), blood indexes (haemoglobin, red blood cells, reticulocytes, fetal haemoglobin) and symptoms improved significantly compared to before treatment (P<0.01), and liver and spleen enlargement were also relieved (P<0.05), with no adverse reactions. The placebo group (n=30) showed no significant improvement in any measure. The trial was small, single-blinded, and used a placebo control, but no long-term follow-up or replication data are provided.
What is still missing: no randomised controlled trials exist for any drug specifically targeting the combined beta-thalassemia-X-linked thrombocytopenia syndrome. The YSSXG trial is limited by small sample size, short duration, and lack of blinding details. No trial has stratified patients by WAS mutation type or thalassemia severity. Funding for a dedicated trial in this rare dual-diagnosis population is absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Hematology · 2010 · 116 citations
Clinical spectrum, pathophysiology and treatment of the Wiskott–Aldrich syndrome
AbstractPURPOSE OF REVIEW: The Wiskott-Aldrich syndrome (WAS), caused by mutations in the WAS gene, is a complex and diverse disorder with X-linked inheritance. This review focuses on recent developments in the understanding of its basic pathophysiology, diverse clinical phenotypes and optimal patient management including novel therapies. RECENT FINDINGS: The protein encoded by the WAS gene is a multifunctional signaling element expressed in immune and hematopoietic cells that plays a critical role in cytoskeletal reorganization, immune synapse formation and intracellular signaling. The type of specific mutation, its location within the gene and its effect on protein expression play a major role in determining an individual patient's clinical phenotype. Recent clinical observations and molecular studies have created a sophisticated picture of the disease spectrum. The improved outcome of stem cell transplantation from related and unrelated matched donors and promising early results from the first clinical gene therapy trial have added new therapeutic options for these patients. SUMMARY: Classic WAS, X-linked thrombocytopenia and X-linked neutropenia are caused by WAS gene mutations, each having a distinct pattern of clinical symptoms and disease severity. New developments in the understanding of these syndromes and novel therapeutic options will have a major impact on the treatment of individuals with WAS mutations.
PULMONARY THROMBOEMBOLISM IN β-THALASSEMIA INTERMEDIA: ARE WE AWARE OF THIS COMPLICATION?
AbstractWe describe a case of pulmonary thromboembolism in a 61-year-old woman with beta-thalassemia intermedia and no other risk factors for thrombosis. Thromboembolism was documented by perfusion lung scan. We review the literature on this uncommon complication of thalassemia intermedia and discuss the pathogenesis and treatment options. A significant relationship between pulmonary thromboembolism and pulmonary hypertension in these patients was noted.
The western spruce budworm in northern Rocky Mountain forests: a review of ecology, past insecticidal treatments and silvicultural practices.
AbstractThalassemia is a congenital hemolytic disease caused by defective globin synthesis resulting in decreased quantity of globin chains. Although the life expectancy of beta-thalassemia patients has markedly improved over the last few years, patients still suffer from many complications of this congenital disease. The presence of a high incidence of thromboembolic events, mainly in beta-thalassemia intermedia, has led to the identification of a hypercoagulable state in these patients. In this paper, we review the molecular and cellular mechanisms leading to hypercoagulability in beta-thalassemia, with a special focus on thalassemia intermedia being the group with the highest incidence of thrombotic events as compared to other types of thalassemias. We also discuss the recommendations for thrombosis prophylaxis in these patients.
Journal of Chinese Integrative Medicine · 2007 · 7 citations
Treatment of β-thalassemia with Bushen Yisui therapy: a randomized controlled trial
AbstractOBJECTIVE: To investigate the efficacy and safety of Yisui Shengxue Granule (YSSXG), a compound traditional Chinese herbal medicine, in treating beta-thalassemia. METHODS: A randomized single-blinded trial was designed. Sixty patients with beta-thalassemia were divided into two groups: 30 patients in YSSXG-treated group and 30 in placebo parallel-control group. The patients in the two groups were assigned to receive either YSSXG or placebo for three months. The patients' symptoms and their blood indexes such as hemoglobin (Hb), red blood cell (RBC), reticulocytes (Ret) and fetal hemoglobin (HBF) were examined before and after the treatment. Meanwhile, the liver and spleen were examined with B-mode ultrasound. RESULTS: In the YSSXG-treated group, the blood indexes (Hb, RBC, Ret and HBF) and the symptoms of the patients were improved after three-month treatment, with statistical significance compared to those before treatment (P<0.01); hepatauxe and splenomegaly were also relieved (P<0.05) and no adverse reactions were monitored. In the placebo parallel-control group, no significant improvement of the blood indexes and symptoms, as well as the hepatauxe and splenomegaly had been found (P>0.05). CONCLUSION: YSSXG demonstrates obvious clinical efficacy and no adverse reactions in treating beta-thalassemia.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
